AstraZeneca Pharma India Q1 FY27 revenue up 30% to INR 6,828 Mn
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
AstraZeneca Pharma India reported Q1 FY2026-27 results with total revenue from operations up 30 percent to INR 6,828 Mn. Profit before exceptional item and tax stood at INR 510 Mn, with profit after exceptional item at INR 507 Mn (clarified as profit before tax, not after tax). Oncology grew 26 percent, Biopharmaceuticals 36 percent and Rare Diseases 35 times. The company secured multiple regulatory approvals for oncology drugs, signed strategic partnerships including a Telangana AI lung cancer screening MoU, and won industry awards.
Strong 30 percent revenue growth across all therapy areas, backed by regulatory approvals, signals healthy business momentum and future expansion.